Welcome to our dedicated page for Corvus Pharmaceu SEC filings (Ticker: CRVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) SEC filings page on Stock Titan provides access to the company’s public reports as filed with the U.S. Securities and Exchange Commission. Corvus is a Delaware-incorporated, clinical-stage biopharmaceutical company whose common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the Nasdaq Global Market. Its filings give structured detail on operations, risk factors, capital structure and governance as it advances immunotherapy programs for cancer and immune diseases.
Through this page, you can review current and periodic reports such as Forms 8-K, which Corvus uses to announce material events including financial results, business updates and board of director changes. For example, recent 8-K filings have furnished press releases on quarterly financial results and described the appointment of a new director to the Board and its committees.
Investors researching CRVS can also use this section to locate annual reports (Form 10-K) and quarterly reports (Form 10-Q), where available, which typically discuss the company’s clinical-stage pipeline, including the ITK inhibitor soquelitinib, the adenosine A2a receptor inhibitor ciforadenant and the anti-CD73 antibody mupadolimab. These filings often outline key clinical programs such as the registration Phase 3 trial in relapsed/refractory peripheral T cell lymphoma and trials in atopic dermatitis and Autoimmune Lymphoproliferative Syndrome.
Stock Titan enhances these documents with AI-powered summaries that highlight important sections, helping readers quickly identify information on clinical development, collaborations, equity structure and risk disclosures without reading every page. Real-time updates from EDGAR mean new CRVS filings, including any future Forms 4 related to insider transactions or proxy statements on executive and director compensation, can be reviewed promptly from a single, organized interface.
Form 4 filing for Corvus Pharmaceuticals (CRVS) dated 07/01/2025 details insider transactions by OrbiMed-affiliated entities.
- Warrant exercise: On 06/27/2025, OrbiMed Private Investments V, LP ("OPI V") exercised 1,397,684 common stock warrants at $3.50 per share.
- Cashless settlement: The transaction was executed on a cashless basis. To satisfy the $4.9 million aggregate exercise price, the issuer withheld 1,176,332 warrant shares, issuing the remaining 221,352 shares to OPI V.
- Open-market disposition: Table I also shows a Code "S" disposal of the same 1,176,332 shares at an average price of $4.1586.
- Post-transaction holdings: OrbiMed’s indirect beneficial ownership declined from 8,341,338 to 7,165,006 common shares, but it remains a >10% shareholder and board-represented director.
- Control structure: OPI V is controlled by OrbiMed Capital GP V LLC (general partner) and OrbiMed Advisors LLC (managing member). Each entity disclaims beneficial ownership except to the extent of pecuniary interest.
The filing signals routine warrant housekeeping before the 06/30/2025 expiry rather than a strategic shift. The cashless feature limits share issuance to 221,352 new shares, a modest dilution relative to OrbiMed’s prior stake. Nonetheless, the simultaneous disposition reduces OrbiMed’s ownership by roughly 14%, which investors may view as a slight negative sentiment indicator.
Corvus Pharmaceuticals, Inc. (CRVS) – Form 4 insider activity dated 06/27/2025
Director and 10% owner Peter A. Thompson, acting through OrbiMed Private Investments V, LP (OPI V), exercised 1,397,684 common stock warrants at $3.50 just before their 06/30/2025 expiry. The warrants were settled on a cashless basis: the issuer withheld 1,176,332 shares (coded “S”) to fund the exercise, and issued 221,352 new shares to OPI V (coded “X”). Following the transactions, Thompson/OPI V’s indirect beneficial ownership stands at 7,165,006 shares.
The filing shows a small net increase in insider ownership and a modest share-count expansion for the company. No open-market sales were reported; the disposition reflects internal share withholding rather than a public sale.